Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

Intervention with citrus flavonoids reverses obesity and improves metabolic syndrome and atherosclerosis in obese Ldlr-/- mice.

Burke AC, Sutherland BG, Telford DE, Morrow MR, Sawyez CG, Edwards JY, Drangova M, Huff MW.

J Lipid Res. 2018 Sep;59(9):1714-1728. doi: 10.1194/jlr.M087387. Epub 2018 Jul 15.

PMID:
30008441
2.

Bempedoic Acid Lowers Low-Density Lipoprotein Cholesterol and Attenuates Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient (LDLR+/- and LDLR-/-) Yucatan Miniature Pigs.

Burke AC, Telford DE, Sutherland BG, Edwards JY, Sawyez CG, Barrett PHR, Newton RS, Pickering JG, Huff MW.

Arterioscler Thromb Vasc Biol. 2018 May;38(5):1178-1190. doi: 10.1161/ATVBAHA.117.310676. Epub 2018 Feb 15.

PMID:
29449335
3.

Regression of atherosclerosis: lessons learned from genetically modified mouse models.

Burke AC, Huff MW.

Curr Opin Lipidol. 2018 Apr;29(2):87-94. doi: 10.1097/MOL.0000000000000493.

PMID:
29369832
4.

Knockdown of Δ-5 Fatty Acid Desaturase Is More Than Just a Fad.

Morrow NM, Huff MW.

Arterioscler Thromb Vasc Biol. 2018 Jan;38(1):6-8. doi: 10.1161/ATVBAHA.117.310382. No abstract available.

PMID:
29282245
5.

Prevention of Diet-Induced Metabolic Dysregulation, Inflammation, and Atherosclerosis in Ldlr-/- Mice by Treatment With the ATP-Citrate Lyase Inhibitor Bempedoic Acid.

Samsoondar JP, Burke AC, Sutherland BG, Telford DE, Sawyez CG, Edwards JY, Pinkosky SL, Newton RS, Huff MW.

Arterioscler Thromb Vasc Biol. 2017 Apr;37(4):647-656. doi: 10.1161/ATVBAHA.116.308963. Epub 2017 Feb 2.

PMID:
28153881
6.

ATP-citrate lyase: genetics, molecular biology and therapeutic target for dyslipidemia.

Burke AC, Huff MW.

Curr Opin Lipidol. 2017 Apr;28(2):193-200. doi: 10.1097/MOL.0000000000000390. Review.

PMID:
28059952
7.

Polygenic Versus Monogenic Causes of Hypercholesterolemia Ascertained Clinically.

Wang J, Dron JS, Ban MR, Robinson JF, McIntyre AD, Alazzam M, Zhao PJ, Dilliott AA, Cao H, Huff MW, Rhainds D, Low-Kam C, Dubé MP, Lettre G, Tardif JC, Hegele RA.

Arterioscler Thromb Vasc Biol. 2016 Dec;36(12):2439-2445. Epub 2016 Oct 20.

PMID:
27765764
8.

PCSK9: Regulation and Target for Drug Development for Dyslipidemia.

Burke AC, Dron JS, Hegele RA, Huff MW.

Annu Rev Pharmacol Toxicol. 2017 Jan 6;57:223-244. doi: 10.1146/annurev-pharmtox-010716-104944. Epub 2016 Aug 8. Review.

PMID:
27575716
9.

Citrus Flavonoids as Regulators of Lipoprotein Metabolism and Atherosclerosis.

Mulvihill EE, Burke AC, Huff MW.

Annu Rev Nutr. 2016 Jul 17;36:275-99. doi: 10.1146/annurev-nutr-071715-050718. Epub 2016 May 4. Review.

PMID:
27146015
10.

Naringenin prevents obesity, hepatic steatosis, and glucose intolerance in male mice independent of fibroblast growth factor 21.

Assini JM, Mulvihill EE, Burke AC, Sutherland BG, Telford DE, Chhoker SS, Sawyez CG, Drangova M, Adams AC, Kharitonenkov A, Pin CL, Huff MW.

Endocrinology. 2015 Jun;156(6):2087-102. doi: 10.1210/en.2014-2003. Epub 2015 Mar 16.

PMID:
25774553
11.

Can a vascular smooth muscle-derived foam-cell really change its spots?

Huff MW, Pickering JG.

Arterioscler Thromb Vasc Biol. 2015 Mar;35(3):492-5. doi: 10.1161/ATVBAHA.115.305225. No abstract available.

PMID:
25717175
12.

G-protein estrogen receptor as a regulator of low-density lipoprotein cholesterol metabolism: cellular and population genetic studies.

Hussain Y, Ding Q, Connelly PW, Brunt JH, Ban MR, McIntyre AD, Huff MW, Gros R, Hegele RA, Feldman RD.

Arterioscler Thromb Vasc Biol. 2015 Jan;35(1):213-21. doi: 10.1161/ATVBAHA.114.304326. Epub 2014 Nov 13.

PMID:
25395619
13.

Gene therapy for hypercholesterolemia: sweet dreams and flying machines.

Huff MW, Assini JM, Hegele RA.

Circ Res. 2014 Aug 29;115(6):542-5. doi: 10.1161/CIRCRESAHA.114.304800. No abstract available.

PMID:
25170090
14.

PPARδ activation attenuates hepatic steatosis in Ldlr-/- mice by enhanced fat oxidation, reduced lipogenesis, and improved insulin sensitivity.

Bojic LA, Telford DE, Fullerton MD, Ford RJ, Sutherland BG, Edwards JY, Sawyez CG, Gros R, Kemp BE, Steinberg GR, Huff MW.

J Lipid Res. 2014 Jul;55(7):1254-66. doi: 10.1194/jlr.M046037. Epub 2014 May 26.

15.

Peroxisome proliferator-activated receptor δ agonist GW1516 attenuates diet-induced aortic inflammation, insulin resistance, and atherosclerosis in low-density lipoprotein receptor knockout mice.

Bojic LA, Burke AC, Chhoker SS, Telford DE, Sutherland BG, Edwards JY, Sawyez CG, Tirona RG, Yin H, Pickering JG, Huff MW.

Arterioscler Thromb Vasc Biol. 2014 Jan;34(1):52-60. doi: 10.1161/ATVBAHA.113.301830. Epub 2013 Oct 24.

PMID:
24158519
16.

Apolipoprotein C-III: going back to the future for a lipid drug target.

Huff MW, Hegele RA.

Circ Res. 2013 May 24;112(11):1405-8. doi: 10.1161/CIRCRESAHA.113.301464. No abstract available.

PMID:
23704213
17.

Peroxisome proliferator-activated receptor δ: a multifaceted metabolic player.

Bojic LA, Huff MW.

Curr Opin Lipidol. 2013 Apr;24(2):171-7. doi: 10.1097/MOL.0b013e32835cc949. Review.

PMID:
23481229
18.

Naringenin prevents cholesterol-induced systemic inflammation, metabolic dysregulation, and atherosclerosis in Ldlr⁻/⁻ mice.

Assini JM, Mulvihill EE, Sutherland BG, Telford DE, Sawyez CG, Felder SL, Chhoker S, Edwards JY, Gros R, Huff MW.

J Lipid Res. 2013 Mar;54(3):711-24. doi: 10.1194/jlr.M032631. Epub 2012 Dec 26.

19.

Citrus flavonoids and lipid metabolism.

Assini JM, Mulvihill EE, Huff MW.

Curr Opin Lipidol. 2013 Feb;24(1):34-40. doi: 10.1097/MOL.0b013e32835c07fd. Review.

PMID:
23254473
20.

The oxysterol 24(s),25-epoxycholesterol attenuates human smooth muscle-derived foam cell formation via reduced low-density lipoprotein uptake and enhanced cholesterol efflux.

Beyea MM, Reaume S, Sawyez CG, Edwards JY, O'Neil C, Hegele RA, Pickering JG, Huff MW.

J Am Heart Assoc. 2012 Jun;1(3):e000810. doi: 10.1161/JAHA.112.000810. Epub 2012 Jun 22.

21.

Citrus flavonoids and the prevention of atherosclerosis.

Mulvihill EE, Huff MW.

Cardiovasc Hematol Disord Drug Targets. 2012 Dec;12(2):84-91. Review.

PMID:
23030447
22.

Activation of peroxisome proliferator-activated receptor δ inhibits human macrophage foam cell formation and the inflammatory response induced by very low-density lipoprotein.

Bojic LA, Sawyez CG, Telford DE, Edwards JY, Hegele RA, Huff MW.

Arterioscler Thromb Vasc Biol. 2012 Dec;32(12):2919-28. doi: 10.1161/ATVBAHA.112.255208. Epub 2012 Sep 27.

PMID:
23023367
23.
24.

Excess of rare variants in non-genome-wide association study candidate genes in patients with hypertriglyceridemia.

Johansen CT, Wang J, McIntyre AD, Martins RA, Ban MR, Lanktree MB, Huff MW, Péterfy M, Mehrabian M, Lusis AJ, Kathiresan S, Anand SS, Yusuf S, Lee AH, Glimcher LH, Cao H, Hegele RA.

Circ Cardiovasc Genet. 2012 Feb 1;5(1):66-72. doi: 10.1161/CIRCGENETICS.111.960864. Epub 2011 Dec 1.

25.

An increased burden of common and rare lipid-associated risk alleles contributes to the phenotypic spectrum of hypertriglyceridemia.

Johansen CT, Wang J, Lanktree MB, McIntyre AD, Ban MR, Martins RA, Kennedy BA, Hassell RG, Visser ME, Schwartz SM, Voight BF, Elosua R, Salomaa V, O'Donnell CJ, Dallinga-Thie GM, Anand SS, Yusuf S, Huff MW, Kathiresan S, Cao H, Hegele RA.

Arterioscler Thromb Vasc Biol. 2011 Aug;31(8):1916-26. doi: 10.1161/ATVBAHA.111.226365. Epub 2011 May 19.

26.

Nobiletin attenuates VLDL overproduction, dyslipidemia, and atherosclerosis in mice with diet-induced insulin resistance.

Mulvihill EE, Assini JM, Lee JK, Allister EM, Sutherland BG, Koppes JB, Sawyez CG, Edwards JY, Telford DE, Charbonneau A, St-Pierre P, Marette A, Huff MW.

Diabetes. 2011 May;60(5):1446-57. doi: 10.2337/db10-0589. Epub 2011 Apr 6.

27.

Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia.

Johansen CT, Wang J, Lanktree MB, Cao H, McIntyre AD, Ban MR, Martins RA, Kennedy BA, Hassell RG, Visser ME, Schwartz SM, Voight BF, Elosua R, Salomaa V, O'Donnell CJ, Dallinga-Thie GM, Anand SS, Yusuf S, Huff MW, Kathiresan S, Hegele RA.

Nat Genet. 2010 Aug;42(8):684-7. doi: 10.1038/ng.628. Epub 2010 Jul 25.

28.
29.

Antiatherogenic properties of flavonoids: implications for cardiovascular health.

Mulvihill EE, Huff MW.

Can J Cardiol. 2010 Mar;26 Suppl A:17A-21A. Review.

PMID:
20386755
30.

Naringenin decreases progression of atherosclerosis by improving dyslipidemia in high-fat-fed low-density lipoprotein receptor-null mice.

Mulvihill EE, Assini JM, Sutherland BG, DiMattia AS, Khami M, Koppes JB, Sawyez CG, Whitman SC, Huff MW.

Arterioscler Thromb Vasc Biol. 2010 Apr;30(4):742-8. doi: 10.1161/ATVBAHA.109.201095. Epub 2010 Jan 28.

PMID:
20110573
31.

APOC1 T45S polymorphism is associated with reduced obesity indices and lower plasma concentrations of leptin and apolipoprotein C-I in aboriginal Canadians.

Lahiry P, Cao H, Ban MR, Pollex RL, Mamakeesick M, Zinman B, Harris SB, Hanley AJ, Huff MW, Connelly PW, Hegele RA.

J Lipid Res. 2010 Apr;51(4):843-8. doi: 10.1194/jlr.P002014. Epub 2009 Oct 6.

32.

Fibroblast growth factor 21 reduces the severity of cerulein-induced pancreatitis in mice.

Johnson CL, Weston JY, Chadi SA, Fazio EN, Huff MW, Kharitonenkov A, Köester A, Pin CL.

Gastroenterology. 2009 Nov;137(5):1795-804. doi: 10.1053/j.gastro.2009.07.064. Epub 2009 Aug 5.

PMID:
19664632
33.

A polygenic basis for four classical Fredrickson hyperlipoproteinemia phenotypes that are characterized by hypertriglyceridemia.

Hegele RA, Ban MR, Hsueh N, Kennedy BA, Cao H, Zou GY, Anand S, Yusuf S, Huff MW, Wang J.

Hum Mol Genet. 2009 Nov 1;18(21):4189-94. doi: 10.1093/hmg/ddp361. Epub 2009 Aug 5.

34.

Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor-null mice with diet-induced insulin resistance.

Mulvihill EE, Allister EM, Sutherland BG, Telford DE, Sawyez CG, Edwards JY, Markle JM, Hegele RA, Huff MW.

Diabetes. 2009 Oct;58(10):2198-210. doi: 10.2337/db09-0634. Epub 2009 Jul 10.

35.

Lipid incorporation inhibits Src-dependent assembly of fibronectin and type I collagen by vascular smooth muscle cells.

Frontini MJ, O'Neil C, Sawyez C, Chan BM, Huff MW, Pickering JG.

Circ Res. 2009 Apr 10;104(7):832-41. doi: 10.1161/CIRCRESAHA.108.187302. Epub 2009 Feb 19.

PMID:
19229059
36.

APOA5 genetic variants are markers for classic hyperlipoproteinemia phenotypes and hypertriglyceridemia.

Wang J, Ban MR, Kennedy BA, Anand S, Yusuf S, Huff MW, Pollex RL, Hegele RA.

Nat Clin Pract Cardiovasc Med. 2008 Nov;5(11):730-7. doi: 10.1038/ncpcardio1326. Epub 2008 Sep 9.

PMID:
18779834
37.

Lipoprotein(a) is associated differentially with carotid stenosis, occlusion, and total plaque area.

Klein JH, Hegele RA, Hackam DG, Koschinsky ML, Huff MW, Spence JD.

Arterioscler Thromb Vasc Biol. 2008 Oct;28(10):1851-6. doi: 10.1161/ATVBAHA.108.169292. Epub 2008 Jul 3.

PMID:
18599799
38.

Polygenic determinants of severe hypertriglyceridemia.

Wang J, Ban MR, Zou GY, Cao H, Lin T, Kennedy BA, Anand S, Yusuf S, Huff MW, Pollex RL, Hegele RA.

Hum Mol Genet. 2008 Sep 15;17(18):2894-9. doi: 10.1093/hmg/ddn188. Epub 2008 Jul 1.

PMID:
18596051
39.

Inhibition of apoB secretion from HepG2 cells by insulin is amplified by naringenin, independent of the insulin receptor.

Allister EM, Mulvihill EE, Barrett PH, Edwards JY, Carter LP, Huff MW.

J Lipid Res. 2008 Oct;49(10):2218-29. doi: 10.1194/jlr.M800297-JLR200. Epub 2008 Jun 27.

40.

Association between the FTO rs9939609 polymorphism and the metabolic syndrome in a non-Caucasian multi-ethnic sample.

Al-Attar SA, Pollex RL, Ban MR, Young TK, Bjerregaard P, Anand SS, Yusuf S, Zinman B, Harris SB, Hanley AJ, Connelly PW, Huff MW, Hegele RA.

Cardiovasc Diabetol. 2008 Mar 13;7:5. doi: 10.1186/1475-2840-7-5.

41.

Common variants APOC3, APOA5, APOE and PON1 are associated with variation in plasma lipoprotein traits in Greenlanders.

Lahiry P, Ban MR, Pollex RL, Feldman RD, Sawyez CG, Huff MW, Young TK, Bjerregaard P, Hegele RA.

Int J Circumpolar Health. 2007 Dec;66(5):390-400.

PMID:
18274205
42.

Association between the -455T>C promoter polymorphism of the APOC3 gene and the metabolic syndrome in a multi-ethnic sample.

Pollex RL, Ban MR, Young TK, Bjerregaard P, Anand SS, Yusuf S, Zinman B, Harris SB, Hanley AJ, Connelly PW, Huff MW, Hegele RA.

BMC Med Genet. 2007 Dec 20;8:80.

43.

Selective up-regulation of LXR-regulated genes ABCA1, ABCG1, and APOE in macrophages through increased endogenous synthesis of 24(S),25-epoxycholesterol.

Beyea MM, Heslop CL, Sawyez CG, Edwards JY, Markle JG, Hegele RA, Huff MW.

J Biol Chem. 2007 Feb 23;282(8):5207-16. Epub 2006 Dec 23.

44.

The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin.

Telford DE, Sutherland BG, Edwards JY, Andrews JD, Barrett PH, Huff MW.

J Lipid Res. 2007 Mar;48(3):699-708. Epub 2006 Nov 27.

45.

Cholesterol absorption inhibitors as a therapeutic option for hypercholesterolaemia.

Burnett JR, Huff MW.

Expert Opin Investig Drugs. 2006 Nov;15(11):1337-51. Review.

PMID:
17040195
46.

Ankyrin G overexpression in Hutchinson-Gilford progeria syndrome fibroblasts identified through biological filtering of expression profiles.

Wang J, Robinson JF, O'Neil CH, Edwards JY, Williams CM, Huff MW, Pickering JG, Hegele RA.

J Hum Genet. 2006;51(11):934-42. Epub 2006 Oct 11.

PMID:
17033732
47.

NPC1L1: evolution from pharmacological target to physiological sterol transporter.

Huff MW, Pollex RL, Hegele RA.

Arterioscler Thromb Vasc Biol. 2006 Nov;26(11):2433-8. Epub 2006 Sep 14. Review.

PMID:
16973966
48.

The ACAT inhibitor avasimibe increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs.

Burnett JR, Telford DE, Barrett PH, Huff MW.

Biochim Biophys Acta. 2005 Dec 30;1738(1-3):10-8. Epub 2005 Dec 22.

PMID:
16427354
49.

A novel inhibitor of oxidosqualene:lanosterol cyclase inhibits very low-density lipoprotein apolipoprotein B100 (apoB100) production and enhances low-density lipoprotein apoB100 catabolism through marked reduction in hepatic cholesterol content.

Telford DE, Lipson SM, Barrett PH, Sutherland BG, Edwards JY, Aebi JD, Dehmlow H, Morand OH, Huff MW.

Arterioscler Thromb Vasc Biol. 2005 Dec;25(12):2608-14. Epub 2005 Oct 6.

PMID:
16210564
50.

Lord of the rings--the mechanism for oxidosqualene:lanosterol cyclase becomes crystal clear.

Huff MW, Telford DE.

Trends Pharmacol Sci. 2005 Jul;26(7):335-40. Review.

PMID:
15951028

Supplemental Content

Support Center